Literature DB >> 8736656

Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status.

G C Kane1, J Varga, E F Conant, P W Spirn, S Jimenez, J E Fish.   

Abstract

Lung involvement accounts for significant morbidity and is a leading cause of mortality in patients with systemic sclerosis (SSc). It has been shown that different patterns of pulmonary involvement are seen in different subtypes of SSc. This paper reports a retrospective review of 72 patients with SSc to determine whether disease classification according to the extent of skin involvement alone (diffuse vs. limited) or autoantibody status was predictive of pulmonary parenchymal involvement. The diagnosis of interstitial lung disease was based on pulmonary function tests and chest radiographs. Restrictive lung disease was common in both limited SSc (lSSc) and diffuse SSc (dSSc), occurring in 30% and 50% of these patients respectively (P = 0.16). Radiographic evidence of significant interstitial disease was also comparable between the groups [nine of 32 lSSc patients (28%) vs. six of 17 dSSc patients (32%), P = n.s.]. No significant difference in mean lung function was found between patients with anti-Scl 70 antibody (n = 12) compared to those without (n = 60) (TLC 79.0 +/- SE 5.1% predicted vs. 82.8 +/- 2.2, P = n.s.; DLCO 63.0 +/- 5.1 vs. 59.7 +/- 2.5, P = n.s.). By contrast, statistically significant differences in mean lung function were found between patients with anticentromere antibody (ACA) (n = 24) and those without ACA (n = 48) (TLC 98.6 +/- SE 3.9% predicted vs. 79.7 +/- 3.1%, P < 0.001); and less frequent radiographic evidence of severe interstitial disease (0 of 17 with significant interstitial changes on chest radiograph vs. 15 of 32 (47%), P = 0.002). It is concluded that classification of SSc patients on the basis of the distribution of skin involvement poorly predicts the occurrence of interstitial lung disease. On the other hand, ACA is highly associated with the absence of interstitial lung disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8736656     DOI: 10.1016/s0954-6111(96)90291-7

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 2.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 3.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

4.  The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis.

Authors:  Anna L Peljto; Mark P Steele; Tasha E Fingerlin; Monique E Hinchcliff; Elissa Murphy; Sofia Podlusky; Mary Carns; Marvin Schwarz; John Varga; David A Schwartz
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

5.  Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis.

Authors:  Predrag Ostojić; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2006-04-28       Impact factor: 2.980

6.  Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study.

Authors:  Philippe R Bauer; Dante N Schiavo; Thomas G Osborn; David L Levin; Jennifer St Sauver; Andrew C Hanson; Darrell R Schroeder; Jay H Ryu
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

Review 7.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Authors:  Flavia V Castelino; John Varga
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

Review 8.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

9.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.

Authors:  Tricia R Cottrell; Robert A Wise; Fredrick M Wigley; Francesco Boin
Journal:  Ann Rheum Dis       Date:  2013-04-20       Impact factor: 19.103

10.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.